Panacea Acquisition Corp. II (PANA): Price and Financial Metrics


Panacea Acquisition Corp. II (PANA): $10.01

0.01 (+0.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PANA Stock Price Chart Interactive Chart >

Price chart for PANA

PANA Price/Volume Stats

Current price $10.01 52-week high $10.23
Prev. close $10.00 52-week low $9.90
Day low $10.00 Volume 1,594
Day high $10.01 Avg. volume 28,902
50-day MA $0.00 Dividend yield N/A
200-day MA $0.00 Market Cap 205.21M

Panacea Acquisition Corp. II (PANA) Company Bio


Panacea Acquisition Corp. II intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the biotechnology sector. The company was incorporated in 2021 and is based in San Francisco, California.


PANA Latest News Stream


Event/Time News Detail
Loading, please wait...

PANA Latest Social Stream


Loading social stream, please wait...

View Full PANA Social Stream

Latest PANA News From Around the Web

Below are the latest news stories about Panacea Acquisition Corp II that investors may wish to consider to help them evaluate PANA as an investment opportunity.

Panacea Acquisition Corp. II Announces Pricing of $150,000,000 Initial Public Offering

SAN FRANCISCO, CA, April 06, 2021 (GLOBE NEWSWIRE) -- Panacea Acquisition Corp. II (the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the pricing of its initial public offering of 15,000,000 Class A ordinary shares at a price of $10.00 per share. The Company is sponsored by EcoR1 Panacea Holdings II, LLC, an affiliate of EcoR1 Capital, LLC. While the Company may pursue an initial business combination target in any industry or geographic location, it intends to focus its search for a target business operating in the biotechnology sector that is domiciled in North America or Europe. The Class A ordinary shares are ...

Yahoo | April 7, 2021

Panacea Announces Effectiveness of Registration Statement for Proposed Business Combination with Nuvation Bio

Panacea Acquisition Corp., a Delaware corporation (the "Company") (NYSE: PANA.U, PANA, PANA WS), announced today that its registration statement on Form S-4 (File No. 333-250036) (as amended, the "Registration Statement"), relating to the previously announced business combination (the "Business Combination") with Nuvation Bio Inc. ("Nuvation Bio"), has been declared effective by the U.S. Securities and Exchange Commission ("SEC") and that it has commenced mailing the definitive proxy statement/prospectus relating to the Special Meeting (the "Special Meeting") of the Company’s stockholders to be held on February 9, 2021 in connection with the Business Combination. The definitive proxy statement/prospectus is being mailed to the Company’s stockholders of record as of the close of business...

Yahoo | January 20, 2021

Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development

Nuvation Bio Inc., a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology, and Panacea Acquisition Corp. (NYSE: PANA), a special purpose acquisition company (SPAC) sponsored by EcoR1 Capital, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, Panacea will be renamed Nuvation Bio Inc. (the Combined Company); its common stock is expected to remain listed on the New York Stock Exchange (NYSE) under the new ticker symbol "NUVB."

Yahoo | October 21, 2020

Read More 'PANA' Stories Here

PANA Price Returns

1-mo 0.10%
3-mo N/A
6-mo -3.84%
1-year N/A
3-year N/A
5-year N/A
YTD -14.44%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.724 seconds.